Innervation and connexin isoform expression during diabetes-related bladder dysfunction: early structural vs. neuronal remodelling.
Urinary bladder dysfunction is a major complication in diabetes mellitus and its mechanism has been attributed to altered neurological function (autonomic and/or peripheral neuropathy). Previous studies have demonstrated impaired nerve deficiencies, including either loss of nerve function and/or anatomical loss of neuromuscular nerve terminals. While the phenomenon of diabetes-related neurological injury is well recognised, its pathogenesis is not well understood. Using a well established rat model of diabetes (streptozotocin model), we investigated the prevalence of sympathetic and parasympathetic nerves and relative prevalence of connexin isoforms (gap junction proteins) during diabetes-related bladder dysfunction. Immunohistochemistry and digital image analysis was used to detect the prevalence of postsynaptic neuronal markers, NOS1 and connexin isoform expressions. Immunohistochemistry showed significant increases in tyrosine hydroxylase (marker of sympathetic innervation) and decreased vesicular acetylcholine transporter (marker of parasympathetic innervation), predominantly in the smooth muscle layer, 3 days after diabetes induction, when compared to age-matched controls. Time-dependent and cell-specific decreases in the connexin 43 isoform, but transient increases in connexin 32 and 26, were also observed in diabetic rats vs. controls (p<0.05). These data suggest that selective and time-dependent expression of gap junction proteins and altered prevalence of sympathetic/parasympathetic innervation are early events during diabetes-related bladder dysfunction and remodelling.
Poladia
D P
DP
Center for Developmental Pharmacology and Toxicology, Columbus Children's Research Institute (W303), 700 Children's Drive, Columbus, OH 43205, USA.
Schanbacher
B
B
Wallace
L J
LJ
Bauer
J A
JA
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D017630:Connexins / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism* / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000378:metabolism*; D004195:Disease Models, Animal; D007150:Immunohistochemistry; D008297:Male; D052248:Nitric Oxide Synthase Type I / Q000378:metabolism; D020033:Protein Isoforms / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D001743:Urinary Bladder / Q000294:innervation / Q000378:metabolism*; D050494:Vesicular Acetylcholine Transport Proteins / Q000378:metabolism
D015415:Biomarkers; D017630:Connexins; D020033:Protein Isoforms; D050494:Vesicular Acetylcholine Transport Proteins; D052248:Nitric Oxide Synthase Type I; D014446:Tyrosine 3-Monooxygenase